State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Thyroid Disease Diagnosis and Treatment Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Am J Physiol Cell Physiol. 2023 Aug 1;325(2):C443-C455. doi: 10.1152/ajpcell.00515.2022. Epub 2023 Jun 27.
Aging and replicative cellular senescence are associated with the reduced therapeutic potential of mesenchymal stem cells (MSCs) on a variety of diseases. This study aimed to determine the mechanism in MSC senescence and further explore a modification strategy to reverse senescence-associated cell dysfunction to improve the therapeutic efficacy of MSCs on acute liver failure (ALF). We found that the adipose tissue-derived MSCs from old mice (oAMSCs) exhibited senescence phenotypes and showed reduced therapeutic efficacy in lipopolysaccharide and D-galactosamine-induced ALF, as shown by the increased hepatic necrosis, liver histology activity index scores, serum liver function indicator levels, and inflammatory cytokine levels. The expression of miR-17-92 cluster members, especially miR-17 and miR-20a, was obviously decreased in oAMSCs and replicatively senescent AMSCs, and was consistent with the decreased oncogene c-Myc level during AMSC senescence and may mediate c-Myc stemness addiction. Further experiments revealed that c-Myc-regulated miR-17-92 expression contributed to increased p21 expression and redox system dysregulation during AMSC senescence. Furthermore, modification of AMSCs with the two key miRNAs in the miR-17-92 cluster mentioned above reversed the senescence features of oAMSCs and restored the therapeutic effect of senescent AMSCs on ALF. In conclusion, the cellular miR-17-92 cluster level is correlated with AMSC senescence and can be used both as an index for evaluating and as a modification target for improving the therapeutic potential of AMSCs. We reported for the first time that c-Myc-regulated miR-17-92 contributed to increased p21 expression and redox system dysregulation during AMSC senescence and was associated with the reduced therapeutic effects of senescent AMSCs on ALF. Moreover, modifying the expression of the miR-17-92 cluster members, especially miR-17 and/or miR-20a, could reverse AMSC senescence. Thus, miR-17-92 cluster can be used both as an index for evaluating and as a modification strategy for improving the therapeutic potential of AMSCs.
衰老和复制性细胞衰老与间充质干细胞(MSCs)在多种疾病中的治疗潜力降低有关。本研究旨在确定 MSC 衰老的机制,并进一步探索一种修饰策略,以逆转衰老相关的细胞功能障碍,提高 MSCs 对急性肝衰竭(ALF)的治疗效果。我们发现,来自老年小鼠的脂肪组织源性 MSCs(oAMSCs)表现出衰老表型,并且在脂多糖和 D-半乳糖胺诱导的 ALF 中治疗效果降低,表现为肝坏死增加,肝组织学活动指数评分,血清肝功能指标水平和炎症细胞因子水平升高。在 oAMSCs 和复制性衰老 AMSCs 中,miR-17-92 簇成员的表达明显降低,尤其是 miR-17 和 miR-20a,与 AMSC 衰老过程中癌基因 c-Myc 水平降低一致,并且可能介导 c-Myc 干性成瘾。进一步的实验表明,c-Myc 调节的 miR-17-92 表达有助于增加 AMSC 衰老过程中的 p21 表达和氧化还原系统失调。此外,用上述 miR-17-92 簇中的两个关键 miRNA 修饰 AMSCs 可逆转 oAMSCs 的衰老特征,并恢复衰老 AMSCs 对 ALF 的治疗作用。总之,细胞 miR-17-92 簇水平与 AMSC 衰老相关,可作为评估和改善 AMSCs 治疗潜力的修饰靶标。我们首次报道,c-Myc 调节的 miR-17-92 通过增加 p21 表达和氧化还原系统失调有助于 AMSC 衰老,并与衰老 AMSCs 对 ALF 的治疗效果降低有关。此外,修饰 miR-17-92 簇成员的表达,特别是 miR-17 和/或 miR-20a,可逆转 AMSC 衰老。因此,miR-17-92 簇可作为评估和改善 AMSCs 治疗潜力的修饰策略。